199 related articles for article (PubMed ID: 23756559)
1. Functional evaluation of circulating hematopoietic progenitors in Noonan syndrome.
Timeus F; Crescenzio N; Baldassarre G; Doria A; Vallero S; Foglia L; Pagliano S; Rossi C; Silengo MC; Ramenghi U; Fagioli F; Cordero di Montezemolo L; Ferrero GB
Oncol Rep; 2013 Aug; 30(2):553-9. PubMed ID: 23756559
[TBL] [Abstract][Full Text] [Related]
2. Myeloproliferative disorder in Noonan syndrome.
Bastida P; García-Miñaúr S; Ezquieta B; Dapena JL; Sanchez de Toledo J
J Pediatr Hematol Oncol; 2011 Jan; 33(1):e43-5. PubMed ID: 20829714
[TBL] [Abstract][Full Text] [Related]
3. In vitro expansion of CD34(+)CD38(-) cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia.
Sakashita K; Kato I; Daifu T; Saida S; Hiramatsu H; Nishinaka Y; Ebihara Y; Ma F; Matsuda K; Saito S; Hirabayashi K; Kurata T; Uyen LT; Nakazawa Y; Tsuji K; Heike T; Nakahata T; Koike K
Leukemia; 2015 Mar; 29(3):606-14. PubMed ID: 25102944
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects.
Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J
Elife; 2022 May; 11():. PubMed ID: 35535491
[TBL] [Abstract][Full Text] [Related]
5. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.
Chan G; Kalaitzidis D; Usenko T; Kutok JL; Yang W; Mohi MG; Neel BG
Blood; 2009 Apr; 113(18):4414-24. PubMed ID: 19179468
[TBL] [Abstract][Full Text] [Related]
6. Juvenile myelomonocytic leukaemia and Noonan syndrome.
Strullu M; Caye A; Lachenaud J; Cassinat B; Gazal S; Fenneteau O; Pouvreau N; Pereira S; Baumann C; Contet A; Sirvent N; Méchinaud F; Guellec I; Adjaoud D; Paillard C; Alberti C; Zenker M; Chomienne C; Bertrand Y; Baruchel A; Verloes A; Cavé H
J Med Genet; 2014 Oct; 51(10):689-97. PubMed ID: 25097206
[TBL] [Abstract][Full Text] [Related]
7. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.
Kratz CP; Niemeyer CM; Castleberry RP; Cetin M; Bergsträsser E; Emanuel PD; Hasle H; Kardos G; Klein C; Kojima S; Stary J; Trebo M; Zecca M; Gelb BD; Tartaglia M; Loh ML
Blood; 2005 Sep; 106(6):2183-5. PubMed ID: 15928039
[TBL] [Abstract][Full Text] [Related]
8. Noonan Syndrome-related Myeloproliferative Disorder Occurring in the Neonatal Period: Case Report and Literature Review.
Hoshino Y; Moriya K; Mitsui-Sekinaka K; Hashimoto Y; Nakayama S; Sajiki D; Muramatsu H; Hagiwara H; Suzuki S; Sekinaka Y; Wakamatsu H; Kawaguchi H; Imai K
J Pediatr Hematol Oncol; 2024 Mar; 46(2):e176-e179. PubMed ID: 38132703
[TBL] [Abstract][Full Text] [Related]
9. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.
Dong L; Yu WM; Zheng H; Loh ML; Bunting ST; Pauly M; Huang G; Zhou M; Broxmeyer HE; Scadden DT; Qu CK
Nature; 2016 Nov; 539(7628):304-308. PubMed ID: 27783593
[TBL] [Abstract][Full Text] [Related]
10. Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia.
Zhang W; Chan RJ; Chen H; Yang Z; He Y; Zhang X; Luo Y; Yin F; Moh A; Miller LC; Payne RM; Zhang ZY; Fu XY; Shou W
J Biol Chem; 2009 Aug; 284(33):22353-22363. PubMed ID: 19509418
[TBL] [Abstract][Full Text] [Related]
11. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.
Nakazawa Y; Matsuda K; Kurata T; Sueki A; Tanaka M; Sakashita K; Imai C; Wilson MH; Koike K
J Hematol Oncol; 2016 Mar; 9():27. PubMed ID: 26983639
[TBL] [Abstract][Full Text] [Related]
12. Use of human androgen receptor gene analysis to aid the diagnosis of JMML in female noonan syndrome patients.
Lavin VA; Hamid R; Patterson J; Alford C; Ho R; Yang E
Pediatr Blood Cancer; 2008 Aug; 51(2):298-302. PubMed ID: 18454468
[TBL] [Abstract][Full Text] [Related]
13. K-RasV14I recapitulates Noonan syndrome in mice.
Hernández-Porras I; Fabbiano S; Schuhmacher AJ; Aicher A; Cañamero M; Cámara JA; Cussó L; Desco M; Heeschen C; Mulero F; Bustelo XR; Guerra C; Barbacid M
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16395-400. PubMed ID: 25359213
[TBL] [Abstract][Full Text] [Related]
14. Reduction of CFU-GM and circulating hematopoietic progenitors in a subgroup of children with chronic neutropenia associated with severe infections and delayed recovery.
Timeus F; Crescenzio N; Foglia L; Doria A; Stillitano MG; Garelli E; Mazzone R; Vivalda L; Vallero S; Ramenghi U; Saracco P
PLoS One; 2019; 14(3):e0213782. PubMed ID: 30870474
[TBL] [Abstract][Full Text] [Related]
15. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
16. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.
Chan RJ; Leedy MB; Munugalavadla V; Voorhorst CS; Li Y; Yu M; Kapur R
Blood; 2005 May; 105(9):3737-42. PubMed ID: 15644411
[TBL] [Abstract][Full Text] [Related]
17. Quantification of granulocyte-macrophage colony-stimulating factor hypersensitivity in juvenile myelomonocytic leukemia by 3H-thymidine assay.
Tanaka M; Takahashi Y; Xu Y; Yoshida N; Yoshimi A; Villalobos IB; Hama A; Nishio N; Hidaka H; Wang Y; Yagasaki H; Kojima S
Leuk Res; 2008 Jul; 32(7):1036-42. PubMed ID: 18164384
[TBL] [Abstract][Full Text] [Related]
18. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.
Frankel AE; Lilly M; Kreitman R; Hogge D; Beran M; Freedman MH; Emanuel PD; McLain C; Hall P; Tagge E; Berger M; Eaves C
Blood; 1998 Dec; 92(11):4279-86. PubMed ID: 9834234
[TBL] [Abstract][Full Text] [Related]
19. Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.
Mulero-Navarro S; Sevilla A; Roman AC; Lee DF; D'Souza SL; Pardo S; Riess I; Su J; Cohen N; Schaniel C; Rodriguez NA; Baccarini A; Brown BD; Cavé H; Caye A; Strullu M; Yalcin S; Park CY; Dhandapany PS; Yongchao G; Edelmann L; Bahieg S; Raynal P; Flex E; Tartaglia M; Moore KA; Lemischka IR; Gelb BD
Cell Rep; 2015 Oct; 13(3):504-515. PubMed ID: 26456833
[TBL] [Abstract][Full Text] [Related]
20. Occurrence of acute lymphoblastic leukemia and juvenile myelomonocytic leukemia in a patient with Noonan syndrome carrying the germline PTPN11 mutation p.E139D.
Pauli S; Steinemann D; Dittmann K; Wienands J; Shoukier M; Möschner M; Burfeind P; Manukjan G; Göhring G; Escherich G
Am J Med Genet A; 2012 Mar; 158A(3):652-8. PubMed ID: 22315187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]